Back Back
ASCO 2020: Key Lung Cancer Studies

CME

Key Studies in Lung Cancer: Independent Conference Coverage of the ASCO 2020 Scientific Meeting

Physicians: Maximum of 1.25 AMA PRA Category 1 Credits™

Released: September 25, 2020

Expiration: September 24, 2021

Stephen Liu
Stephen Liu, MD
Zofia Piotrowska
Zofia Piotrowska, MD
CME/CE Information

Activity

Progress
1
Course Completed
Claim Certificate

References

  1. Herbst RS, Tsuboi M, John T, et al. Osimertinib as adjuvant therapy in patients (pts) with stage IB-IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA. J Clin Oncol. Program and abstracts of the 2020 Annual Meeting of the American Society of Clinical Oncology; May 29 - June 2, 2020; Virtual. Abstract LBA5.
  2. Kelly K, Altorki NK, Eberhardt WEE, et al. Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non–small-cell lung cancer (RADIANT): a randomized, double-blind, phase III trial. J Clin Oncol. 2015;33:4007-14.
  3. Soria J-C, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113-125.
  4. Pennell NA, Neal JW, Chaft JE, et al. SELECT: A Phase II trial of adjuvant erlotinib in patients with resected epidermal growth factor receptor–mutant non–small-cell lung cancer. J Clin Oncol. 2019;37:97-104.
  5. Zhong W-Z, Wang Q, Mao W-M, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomized, open-label, phase 3 study. Lancet Oncol. 2018;19:139-148.
  6. Wu Y-L, Zhong W, Wang Q, et al. Gefitinib (G) versus vinorelbine + cisplatin (VP) as adjuvant treatment in stage II-IIIA (N1-N2) non-small-cell lung cancer (NSCLC) with EGFR-activating mutation (ADJUVANT): a randomized, phase III trial (CTONG 1104). Program and abstracts of the 2017 Annual Meeting of the American Society of Clinical Oncology; June 2-6, 2017; Chicago, Illinois. Abstract 8500.
  7. Wu Y-L, Zhong W, Wang Q, et al. CTONG1104: adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—final overall survival analysis of the randomized phase III trial 1 analysis of the randomized phase III trial. Program and abstracts of the 2020 Annual Meeting of the American Society of Clinical Oncology; May 29 - June 2, 2020; Virtual. Abstract 9005.
  8. Cortés ÁA, Urquizu LC, Cubero JH. Adjuvant chemotherapy in non-small cell lung cancer: state-of-the-art. Transl Lung Cancer Res. 2015;4:191-197.
  9. Peters S, Ramalingam SS, Paz-Ares L, et al. LBA4_PR: Nivolumab (NIVO) + low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 Part 1 final analysis. Ann Oncol. 2019;30(Suppl 5):LBA4_PR.
  10. Hellman MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378:2093-2104.
  11. Ramalingam SS, Ciuleanu TE, Pluzanski A, et al. Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: three-year update from CheckMate 227 Part 1. J Clin Oncol. Program and abstracts of the 2020 Annual Meeting of the American Society of Clinical Oncology; May 29 - June 2, 2020; Virtual. Abstract 9500.
  12. Reck M, Ciuleanu TE, Cobo Dols M, et al. Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate9LA. Program and abstracts of the 2020 Annual Meeting of the American Society of Clinical Oncology; May 29 - June 2, 2020; Chicago, Illinois. Abstract 9501.
  13. Nivolumab package insert. Princeton, NJ: Bristol-Myers Squibb Company; 2020.
  14. Gadgeel S, Rodríguez-Abreu D, Speranza G, et al. Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol. 2020;38:1505-1517.
  15. Adashek JJ, Subbiah IM, Matos I, et al. Hyperprogression and immunotherapy: fact, fiction, or alternative fact? Trends Cancer. 2020;6:181-191.
  16. Bendell JC, Bedard P, Bang Y-J, et al. CT302 - Phase Ia/Ib dose-escalation study of the anti-TIGIT antibody tiragolumab as a single agent and in combination with atezolizumab in patients with advanced solid tumors. Program and abstracts of the 2020 American Association for Cancer Research Virtual Annual Meeting; June 22-24, 2020; Virtual. Abstract CT302.
  17. Rodríguez-Abreu D, Johnson ML, Hussein MA, et al. Primary analysis of a randomized, double-blind, phase III study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE). Program and abstracts of the 2020 Annual Meeting of the American Society of Clinical Oncology; May 29 - June 2, 2020; Virtual. Abstract 9503.
  18. ClinicalTrials.gov. A study of tiragolumab in combination with atezolizumab compared with placebo in combination with atezolizumab in patients with previously untreated locally advanced unresectable or metastatic PD-L1-selected non-small cell lung cancer (SKYSCRAPER-01). Available at: https://clinicaltrials.gov/ct2/show/NCT04294810. Accessed August 30, 2020.
  19. Wang X and Zeng M. First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332). Program and abstracts of the 2020 Annual Meeting of the American Society of Clinical Oncology; May 29 - June 2, 2020; Virtual. Abstract 9508.
  20. Gomez DR, Blumenschein GR, Lee JJ, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomized, controlled, phase 2 study. Lancet Oncol. 2016:17:1672-1682.
  21. Li AM, Boichard A, Felip E, et al. New therapeutic approaches to overcoming resistant EGFR exon 20 alterations. Crit Rev Oncol Hematol. 2020;15:102990.
  22. Noronha V, Patil VM, Joshi A, et al. Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer. J Clin Oncol. 2020;38:124-136.
  23. Hosomi Y, Morita S, Sugawara S, et al. Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 Study. J Clin Oncol. 2020;38:115-123.
  24. Gainor JF, Curigliano G, Kim D-W, et al. Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC). Program and abstracts of the 2020 Annual Meeting of the American Society of Clinical Oncology; May 29 - June 2, 2020; Virtual. Abstract 9515.
  25. Gainor JF, Lee DH, Curigliano G, et al. Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC). Program and abstracts of the 2019 Annual Meeting of the American Society of Clinical Oncology; May 31 - June 4, 2019; Chicago, Illinois. Abstract 9008.
  26. Selpercatinib package insert. Indianapolis, IN; Lilly USA, LLC; 2020.
  27. ClinicalTrials.gov. Clinical study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type advanced non-small cell lung cancer. Available at: https://clinicaltrials.gov/ct2/show/NCT02414139. Accessed August 30, 2020.
  28. Wolf J, Seto T, Han J-H, et al. Capmatinib (INC280) in METΔex14-mutated advanced non-small cell lung cancer (NSCLC): efficacy data from the phase II GEOMETRY mono-1 study. Program and abstracts of the 2019 Annual Meeting of the American Society of Clinical Oncology; May 31 - June 4, 2019; Chicago, Illinois. Abstract 9004.
  29. Capmatinib package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2020.
  30. Wolf J, Overbeck TR, Han J-Y, et al. Capmatinib in patients with high-level MET-amplified advanced non-small cell lung cancer (NSCLC): results from the phase 2 GEOMETRY mono-1 study. Program and abstracts of the 2020 Annual Meeting of the American Society of Clinical Oncology; May 29 - June 2, 2020; Virtual. Abstract 9509.
  31. ClinicalTrials.gov. DS-8201a in human epidermal growth factor receptor 2 (HER2)-expressing or -mutated non-small cell lung cancer. Available at: https://clinicaltrials.gov/ct2/show/NCT03505710. Accessed August 30, 2020.
  32. Trastuzumab deruxtecan package insert. Basking Ridge, New Jersey: Daiichi Sankyo, Inc.; 2019.
  33. Mazieres J, Peters S, Lepage B, et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol. 2013;31:1997-2003.
  34. Arcila ME, Chaft JE, Nafa K, et al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res. 2012;18:4910-4918.
  35. Smit EF, Nakagawa K, Nagasaka M, et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): interim results of DESTINY-Lung01. J Clin Oncol. Program and abstracts of the 2020 Annual Meeting of the American Society of Clinical Oncology; May 29 - June 2, 2020; Virtual. Abstract 9504.
  36. Robichaux JP, Elamin YY, Tan Z, et al. Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med. 2018;24:638-646.
  37. Neal J, Doebele R, Riely G, et al. Safety, PK, and preliminary antitumor activity of the oral EGFR/HER2 exon 20 inhibitor TAK-788 in NSCLC. Program and abstracts of the 19th World Conference on Lung Cancer of the International Association for the Study of Lung Cancer (IASLC); September 23-26, 2018; Toronto, Canada. Abstract P1.13-44.
  38. Jänne PA, Neal JW, Camidge R, et al. Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions. Program and abstracts of the 2019 Annual Meeting of the American Society of Clinical Oncology; May 31 - June 4, 2019; Chicago, Illinois. Abstract 9007.
  39. Le X, Goldman J, Clarke J, et al. Poziotinib activity and durability of responses in previously treated EGFR exon 20 NSCLC patients - a Phase 2 study. Program and abstracts of the 2020 American Association for Cancer Research Virtual Annual Meeting; June 22-24, 2020; Virtual.. Abstract CT081.
  40. Li BT, Shen R, Buonocore D, et al. Ado-trastuzumab emtansine in patients with HER2 mutant lung cancers: results from a phase II basket trial. Program and abstracts of the 2019 Annual Meeting of the American Society of Clinical Oncology; June 2-6, 2017; Chicago, Illinois. Abstract 8510.
  41. Atezolizumab package insert. South San Francisco, CA: Genentech, Inc; 2020.
  42. Durvalumab package insert. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2017.
  43. Horn L, Mansfield AS, Szczesna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220-2229.
  44. Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase 3 trial. Lancet. 2019;394:1929-1939.
  45. Rudin CM, Awad MM, Navarro A, et al. KEYNOTE-604: pembrolizumab (pembro) or placebo plus etoposide and platinum (EP) as first-line therapy for extensive-stage (ES) small-cell lung cancer (SCLC). Program and abstracts of the 2020 Annual Meeting of the American Society of Clinical Oncology; May 29 - June 2, 2020; Virtual. Abstract 9001.
  46. Rudin CM, Awad MM, Navarro A, et al. Pembrolizumab or placebo plus etoposide and platinum as first-Line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study. J Clin Oncol. 2020;38:2369-2379.
  47. Paz-Ares LG, Dvorkin M, Chen Y, et al. Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): updated results from the phase III CASPIAN study. Program and abstracts of the 2020 Annual Meeting of the American Society of Clinical Oncology; May 29 - June 2, 2020; Virtual. Abstract 9002.
  48. Lurbinectedin package insert. Palo Alto, CA: Jazz Pharmaceuticals, Inc.; 2020.
  49. Trigo J, Subbiah V, Besse B, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol. 2020;21:645-654.
  50. Aix SP, Cote GM, Gonzalez AF, et al. Lurbinectedin (LUR) in combination with irinotecan (IRI) in patients (pts) with advanced solid tumors: updated results from a phase Ib-II trial. Program and abstracts of the 2020 Annual Meeting of the American Society of Clinical Oncology; May 29 - June 2, 2020; Virtual. Abstract 3514.
  51. ClinicalTrials.gov. Study of irinotecan liposome injection (ONIVYDE®) in patients with small cell lung cancer (RESILIENT). Available at: https://clinicaltrials.gov/ct2/show/NCT03088813. Accessed August 30, 2020.
  52. Spigel DR, Paz-Ares L, Chen Y, et al. RESILIENT part I, an open-label, safety run-in of liposomal irinotecan in adults with small cell lung cancer (SCLC) who have progressed with platinum-based first-line (1L) therapy: subgroup analyses by platinum sensitivity. Program and abstracts of the 2020 Annual Meeting of the American Society of Clinical Oncology; May 29 - June 2, 2020; Virtual. Abstract 9069.
  53. Pralsetinib package insert. Cambridge, MA: Blueprint Medicines Corporation; 2020.

BACK | NEXT
Claim Certificate